Skip to Content
Center for International Blood and Marrow Transplant Research

MM18-04

Main Content

Busulfan, melphalan, and bortezomib versus high-dose melphalan as a conditioning regimen for autologous transplants in multiple myeloma: Long term follow up of a novel conditioning regimen.

Study #: MM18-04

Study Status: Published

Presentation(s)

2019, ASH (Poster)

Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: Long term follow up of a novel high dose regimen.

Citation

Hagen P, D'Souza A, Hari P, Davila O, Zhang M-J, Vesole DH, Smith SE, Rodriguez TE, Stiff PJ.

Leukemia & Lymphoma. 2020, Dec 01: 61(14): 61(14):3484-3492. doi: 10.1080/10428194.2020.1811275. Epub 2020, Aug 31. PMCID:PMC7786301.

PubMed

PMID: 32865474

Abstract